Fore Capital’s Matinas BioPharma MTNB Stock Holding History

Fore Capital’s Portfolio MTNB Stock Details MTNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-200	Closed	-$8K	–	36
2022 Q1	$8K	Hold	200	–	–	﹤0.01%	44
2021 Q4	$10K	Hold	200	–	–	﹤0.01%	45
2021 Q3	$13K	Hold	200	–	–	0.01%	45
2021 Q2	$8K	Hold	200	–	–	﹤0.01%	59
2021 Q1	$11K	Hold	200	–	–	﹤0.01%	62
2020 Q4	$14K	Hold	200	–	–	﹤0.01%	65
2020 Q3	$8K	Hold	200	–	–	﹤0.01%	31
2020 Q2	$8K	Hold	200	–	–	﹤0.01%	56
2020 Q1	$6K	Hold	200	–	–	﹤0.01%	68
2019 Q4	$23K	Hold	200	–	–	﹤0.01%	66
2019 Q3	$6K	Hold	200	–	–	﹤0.01%	47
2019 Q2	$9K	Hold	200	–	–	﹤0.01%	71
2019 Q1	$11K	Hold	200	–	–	﹤0.01%	63
2018 Q4	$6K	Hold	200	–	–	﹤0.01%	55
2018 Q3	$9K	Hold	200	–	–	﹤0.01%	57
2018 Q2	$4K	Hold	200	–	–	﹤0.01%	35
2018 Q1	$8K	Buy	+200	New	+$10.6K	﹤0.01%	62

Other funds holding MTNB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SIG

Sargent Investment Group Bethesda, Maryland $832M AUM 24.89% 1-Year Est. Return

NRS

Neville Rodie & Shaw New York $1.55B AUM 46.95% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AWA

Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

SCA

STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.57B AUM 26.96% 1-Year Est. Return

Fore Capital's MTNB Position: Q2 2022 in Review

Fore Capital sold out of Matinas BioPharma (MTNB) in Q2 2022, closing a stake of 200 shares — an estimated $8K sold.

Fore Capital first reported a position in MTNB in Q1 2018 and held it in 17 quarters. The position peaked at $23K in Q4 2019. 50 funds tracked by Wall St. Rank hold MTNB as of Q2 2022.

Fore Capital reported no remaining Matinas BioPharma position as of Q2 2022 after selling out during the quarter.
Fore Capital sold 200 Matinas BioPharma shares in Q2 2022, an estimated $8K.
Fore Capital first reported a position in Matinas BioPharma in Q1 2018 and held it in 17 quarters.
Fore Capital's Matinas BioPharma position peaked at $23K in Q4 2019.
50 funds tracked by Wall St. Rank held Matinas BioPharma as of Q2 2022.

Based on Fore Capital's 13F filing for Q2 2022, filed 8 Aug 2022.